How well does Hernexeos(Zongertinib) work?

Clinical trials demonstrated a high objective response rate in patients with HER2-mutant NSCLC.

Clinical Benefits

In the pivotal Beamion LUNG-1 trial involving patients with previously treated, metastatic HER2 TKD-mutant non-squamous NSCLC, HERNEXEOS showed significant efficacy. The confirmed objective response rate was 75%, comprising both complete and partial responses. Among responders, 58% experienced a duration of response lasting six months or longer. Antitumor activity was also observed in patients with measurable central nervous system metastases at baseline.